PD-1 Cancer Research Results

PD-1, Programmed Death-1: Click to Expand ⟱
Source:
Type: protein
PD-1 (Programmed Death-1) is a protein that plays a crucial role in the immune system's ability to fight cancer. It is a checkpoint protein that helps regulate the immune response by preventing the immune system from attacking healthy cells.
PD-1 is often exploited by cancer cells to evade the immune system. Cancer cells can produce proteins that bind to PD-1, inhibiting the immune response and allowing the cancer cells to grow and proliferate unchecked.

However, researchers have discovered that blocking the PD-1 pathway can help restore the immune system's ability to fight cancer. This has led to the development of PD-1 inhibitors, a class of cancer therapies that target the PD-1 protein.

PD-1: Upregulated on tumor-infiltrating lymphocytes (TILs), reflecting chronic antigen exposure and an “exhausted” T cell phenotype.
PD-L1 and PD-L2: Frequently overexpressed by many tumor types (e.g., non–small cell lung cancer, melanoma, renal cell carcinoma, head and neck cancers).
Scientific Papers found: Click to Expand⟱
541- Akk,    Akkermansia muciniphila as a Next-Generation Probiotic in Modulating Human Metabolic Homeostasis and Disease Progression: A Role Mediated by Gut-Liver-Brain Axes?
- Review, NA, NA
GutMicro↑, PD-1↝, CD8+↑, IL8↑,
542- Akk,  immuno,    Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
CD4+↑, CXCc↑, PD-1↝,
557- ART/DHA,    Artemisinin and Its Derivatives in Cancer Care
- Review, Var, NA
*BioAv↓, *BioAv↑, Apoptosis↑, EGFR↓, CD31↓, Ki-67↓, P53↓, TfR1/CD71↑, P-gp↓, PD-1↝,
741- Bor,    Boron Derivatives Inhibit the Proliferation of Breast Cancer Cells and Affect Tumor-Specific T Cell Activity In Vitro by Distinct Mechanisms
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
MOB1↓, PD-L1↑, p‑YAP/TEAD↝, IFN-γ↓, sFasL↑, Perforin↓, GranA↓, GranB↓, GNLY↓, PD-1↑,
2017- CAP,    Spice Up Your Kidney: A Review on the Effects of Capsaicin in Renal Physiology and Disease
- Review, Var, NA
RenoP↑, AntiTum↑, AMPK↑, mTOR↑, PD-1↓, PD-L1↓,
451- CUR,    The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer
- vitro+vivo, HNSCC, SCC15 - vitro+vivo, HNSCC, SNU1076 - vitro+vivo, HNSCC, SNU1041
TumCMig↓, TumCG↓, PD-L1↓, PD-L2↓, Galectin-9↓, EMT↓, T-Cell↑, TILs↑, PD-1↓, TIM-3↓, CD4+↓, CD25+↓, FoxP3+↓, E-cadherin↑, CD8+↑, IFN-γ↑,
1621- EA,    The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art
- Review, Var, NA
AntiCan↑, Apoptosis↑, TumCP↓, TumMeta↓, TumCI↓, TumAuto↑, VEGFR2/KDR/Flk1↓, MAPK↓, PI3K↓, Akt↓, PD-1↓, NOTCH↓, PCNA↓, Ki-67↓, cycD1/CCND1↓, CDK2↑, CDK6↓, Bcl-2↓, cl‑PARP↑, BAX↑, Casp3↑, DR4↑, DR5↑, Snail↓, MMP2↓, MMP9↓, TGF-β↑, PKCδ↓, β-catenin/ZEB1↓, SIRT1↓, HO-1↓, ROS↑, CHOP/DDIT3↑, Cyt‑c↑, MMP↓, OCR↓, AMPK↑, Hif1a↓, NF-kB↓, E-cadherin↑, Vim↓, EMT↓, LC3II↑, CIP2A↓, GLUT1↓, PDH↝, MAD↓, LDH↓, GSTs↑, NOTCH↓, survivin↓, XIAP↓, ER Stress↑, ChemoSideEff↓, ChemoSen↑,
6981- Form,    Formononetin: a review of its source, pharmacology, drug combination, toxicity, derivatives, and drug delivery systems
- Review, Var, NA - Review, AD, NA - Review, PSA, NA
BioAv↝, *memory↑, *ROS↓, *AChE↓, *NF-kB↓, *Keap1↝, *NRF2↑, *Inflam↓, *PGC-1α↝, *HO-1↓, *p‑tau↓, *cognitive↑, *BDNF↑, *5HT↑, *Stroke↓, *PARP1↓, *AIF↓, *Casp3↓, NP/CIPN↓, *neuroP↑, *NGF↑, *TNF-α↓, *IL1β↓, *IL18↓, *IL6↓, *VCAM-1↓, *pol-M2 MC↑, *hepatoP↑, *AST↓, *ALAT↓, *LC3II↑, *Beclin-1↑, *p62↑, *COX2↑, *MMP↑, *ATP↑, *GSH↑, *Catalase↑, *GPx↑, *MDA↓, *antiPs↑, *AntiDiabetic↑, *glucose↓, *Insulin↑, *GutMicro↑, *Obesity↓, COX2↓, cycD1/CCND1↓, TumCCA↑, EGFR↓, GSK‐3β↑, Mcl-1↓, *toxicity↓, TumCP↓, Hif1a↓, VEGF↓, ERK↓, LAMs↓, Cyt‑c↑, Casp9↑, Casp3↑, PARP↑, TumCD↑, mitA↑, BACH1↓, P53↓, ROS↑, PD-1↓, NF-kB↓, *Bacteria↓, *AntiViral↑, *mt-ROS?, *PI3K↓, *chemoP↑, ChemoSen↑, eff↑, *toxicity↓, *BioAv↑, *BioAv↑, *eff↑,
6968- Form,    Formononetin represses cervical tumorigenesis by interfering with the activation of PD-L1 through MYC and STAT3 downregulation
- in-vitro, Cerv, NA
PD-1↓, Myc↓, STAT3↓,
7016- Fuc,    Therapies from Fucoidan: New Developments
- Review, Var, NA
*Bacteria↓, *BioAv↓, *Dose↝, *GutMicro↑, PD-1↝, ROS⇅, cl‑Casp↑, cl‑PARP↑, RadioS↑, *radioP↑, *neuroP↑, *Aβ↓,
2919- LT,    Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence
- Review, Var, NA
RadioS↑, ChemoSen↑, chemoP↑, *lipid-P↓, *Catalase↑, *SOD↑, *GPx↑, *GSTs↑, *GSH↑, *TNF-α↓, *IL1β↓, *Casp3↓, *IL10↑, NRF2↓, HO-1↓, NQO1↓, GSH↓, MET↓, p‑MET↓, p‑Akt↓, HGF/c-Met↓, NF-kB↓, Bcl-2↓, SOD2↓, Casp8↑, Casp3↑, PARP↑, MAPK↓, NLRP3↓, ASC↓, Casp1↓, IL6↓, IKKα↓, p‑p65↓, p‑p38↑, MMP2↓, ICAM-1↓, EGFR↑, p‑PI3K↓, E-cadherin↓, ZO-1↑, N-cadherin↓, CLDN1↓, β-catenin/ZEB1↓, Snail↓, Vim↑, ITGB1↓, FAK↓, p‑Src↓, Rac1↓, Cdc42↓, Rho↓, PCNA↓, Tyro3↓, AXL↓, CEA↓, NSE↓, SOD↓, Catalase↓, GPx↓, GSR↓, GSTs↓, GSH↓, VitE↓, VitC↓, CYP1A1↓, cFos↑, AR↓, AIF↑, p‑STAT6↓, p‑MDM2↓, NOTCH1↓, VEGF↓, H3↓, H4↓, HDAC↓, SIRT1↓, ROS↑, DR5↑, Cyt‑c↑, p‑JNK↑, PTEN↓, mTOR↓, CD34↓, FasL↑, Fas↑, XIAP↓, p‑eIF2α↑, CHOP/DDIT3↑, LC3II↑, PD-1↓, STAT3↓, IL2↑, EMT↓, cachexia↓, BioAv↑, *Half-Life↝, *eff↑,
5254- NCL,    The magic bullet: Niclosamide
- Review, Var, NA
Wnt↓, β-catenin/ZEB1↓, RAS↓, STAT3↓, NOTCH↓, E2Fs↓, mTOR↓, eff↑, PD-1↓, PD-L1↓, BioAv↝, toxicity↓, BioAv↑, ETC↑, NADH:NAD↓, TCA↑, Warburg↓, Diff↑, AMPK↑, P53↑, PP2A↑, HIF-1↓, KRAS↓, Myc↓, RadioS↑, ChemoSen↑, Dose↝, Dose↑,
3092- RES,    Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action
- Review, BC, MDA-MB-231 - Review, BC, MCF7
TumCP↓, tumCV↓, TumCI↓, TumMeta↓, *antiOx↑, *cardioP↑, *Inflam↓, *neuroP↑, *Keap1↓, *NRF2↑, *ROS↓, p62↓, IL1β↓, CRP↓, VEGF↓, Bcl-2↓, MMP2↓, MMP9↓, FOXO4↓, POLD1↓, CK2↓, MMP↓, ROS↑, Apoptosis↑, TumCCA↑, Beclin-1↓, Ki-67↓, ATP↓, GlutMet↓, PFK↓, TGF-β↓, SMAD2↓, SMAD3↓, Vim?, Snail↓, Slug↓, E-cadherin↑, EMT↓, Zeb1↓, Fibronectin↓, IGF-1↓, PI3K↓, Akt↓, HO-1↑, eff↑, PD-1↓, CD8+↑, Th1 response↑, CSCs↓, RadioS↑, SIRT1↑, Hif1a↓, mTOR↓,
1048- RosA,  GSL,    Rosmarinic acid in combination with ginsenoside Rg1 suppresses colon cancer metastasis via co-inhition of COX-2 and PD1/PD-L1 signaling axis
- in-vivo, Colon, MC38
TumCMig↓, TumCI↓, PD-1↓, COX2↓, PD-L1↓,
4836- Uro,    Urolithin-A Promotes CD8+ T Cell–mediated Cancer Immunosurveillance via FOXO1 Activation
- in-vitro, Var, NA
FOXO1↑, TumCG↓, PD-1↓, TIM-3↓,

Showing Research Papers: 1 to 15 of 15

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 15

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↓, 1,   CYP1A1↓, 1,   GPx↓, 1,   GSH↓, 2,   GSR↓, 1,   GSTs↓, 1,   GSTs↑, 1,   HO-1↓, 2,   HO-1↑, 1,   MAD↓, 1,   NQO1↓, 1,   NRF2↓, 1,   ROS↑, 4,   ROS⇅, 1,   SOD↓, 1,   SOD2↓, 1,   VitC↓, 1,   VitE↓, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

TfR1/CD71↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 1,   ATP↓, 1,   ETC↑, 1,   MMP↓, 2,   OCR↓, 1,   XIAP↓, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 3,   GlutMet↓, 1,   LDH↓, 1,   NADH:NAD↓, 1,   PDH↝, 1,   PFK↓, 1,   POLD1↓, 1,   SIRT1↓, 2,   SIRT1↑, 1,   TCA↑, 1,   Warburg↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 2,   p‑Akt↓, 1,   Apoptosis↑, 3,   BAX↑, 1,   Bcl-2↓, 3,   cl‑Casp↑, 1,   Casp1↓, 1,   Casp3↑, 3,   Casp8↑, 1,   Casp9↑, 1,   CK2↓, 1,   Cyt‑c↑, 3,   DR4↑, 1,   DR5↑, 2,   Fas↑, 1,   FasL↑, 1,   GranA↓, 1,   GranB↓, 1,   HGF/c-Met↓, 1,   p‑JNK↑, 1,   MAPK↓, 2,   Mcl-1↓, 1,   p‑MDM2↓, 1,   Myc↓, 2,   p‑p38↑, 1,   Perforin↓, 1,   sFasL↑, 1,   survivin↓, 1,   TumCD↑, 1,   p‑YAP/TEAD↝, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

H3↓, 1,   H4↓, 1,   tumCV↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 2,   p‑eIF2α↑, 1,   ER Stress↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1↓, 1,   LC3II↑, 2,   p62↓, 1,   TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

P53↓, 2,   P53↑, 1,   PARP↑, 2,   cl‑PARP↑, 2,   PCNA↓, 2,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↑, 1,   cycD1/CCND1↓, 2,   E2Fs↓, 1,   mitA↑, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD34↓, 1,   cFos↑, 1,   CIP2A↓, 1,   CSCs↓, 1,   Diff↑, 1,   EMT↓, 4,   ERK↓, 1,   FOXO1↑, 1,   FOXO4↓, 1,   GSK‐3β↑, 1,   HDAC↓, 1,   IGF-1↓, 1,   mTOR↓, 3,   mTOR↑, 1,   NOTCH↓, 3,   NOTCH1↓, 1,   PI3K↓, 2,   p‑PI3K↓, 1,   PTEN↓, 1,   RAS↓, 1,   p‑Src↓, 1,   STAT3↓, 3,   p‑STAT6↓, 1,   TumCG↓, 2,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

AXL↓, 1,   BACH1↓, 1,   CD31↓, 1,   Cdc42↓, 1,   CEA↓, 1,   CLDN1↓, 1,   E-cadherin↓, 1,   E-cadherin↑, 3,   FAK↓, 1,   Fibronectin↓, 1,   Galectin-9↓, 1,   ITGB1↓, 1,   Ki-67↓, 3,   KRAS↓, 1,   LAMs↓, 1,   MET↓, 1,   p‑MET↓, 1,   MMP2↓, 3,   MMP9↓, 2,   MOB1↓, 1,   N-cadherin↓, 1,   PKCδ↓, 1,   Rac1↓, 1,   Rho↓, 1,   Slug↓, 1,   SMAD2↓, 1,   SMAD3↓, 1,   Snail↓, 3,   TGF-β↓, 1,   TGF-β↑, 1,   TumCI↓, 3,   TumCMig↓, 2,   TumCP↓, 3,   TumMeta↓, 2,   Tyro3↓, 1,   Vim?, 1,   Vim↓, 1,   Vim↑, 1,   Zeb1↓, 1,   ZO-1↑, 1,   β-catenin/ZEB1↓, 3,  

Angiogenesis & Vasculature(tgid=14) ⓘ

EGFR↓, 2,   EGFR↑, 1,   HIF-1↓, 1,   Hif1a↓, 3,   VEGF↓, 3,   VEGFR2/KDR/Flk1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 1,   P-gp↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

ASC↓, 1,   CD25+↓, 1,   CD4+↓, 1,   CD4+↑, 1,   COX2↓, 2,   CRP↓, 1,   CXCc↑, 1,   FoxP3+↓, 1,   GNLY↓, 1,   ICAM-1↓, 1,   IFN-γ↓, 1,   IFN-γ↑, 1,   IKKα↓, 1,   IL1β↓, 1,   IL2↑, 1,   IL6↓, 1,   IL8↑, 1,   NF-kB↓, 3,   p‑p65↓, 1,   PD-1↓, 10,   PD-1↑, 1,   PD-1↝, 4,   PD-L1↓, 4,   PD-L1↑, 1,   PD-L2↓, 1,   T-Cell↑, 1,   Th1 response↑, 1,   TILs↑, 1,  

Cellular Microenvironment(tgid=17) ⓘ

TIM-3↓, 2,  

Protein Aggregation(tgid=19) ⓘ

NLRP3↓, 1,   PP2A↑, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 1,   CDK6↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 2,   BioAv↝, 2,   ChemoSen↑, 4,   Dose↑, 1,   Dose↝, 1,   eff↑, 3,   RadioS↑, 4,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 1,   CEA↓, 1,   CRP↓, 1,   EGFR↓, 2,   EGFR↑, 1,   GutMicro↑, 1,   IL6↓, 1,   Ki-67↓, 3,   KRAS↓, 1,   LDH↓, 1,   Myc↓, 2,   NSE↓, 1,   PD-L1↓, 4,   PD-L1↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   AntiTum↑, 1,   cachexia↓, 1,   chemoP↑, 1,   ChemoSideEff↓, 1,   NP/CIPN↓, 1,   RenoP↑, 1,   toxicity↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

CD8+↑, 3,  
Total Targets: 223

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

Stroke↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Catalase↑, 2,   GPx↑, 2,   GSH↑, 2,   GSTs↑, 1,   HO-1↓, 1,   Keap1↓, 1,   Keap1↝, 1,   lipid-P↓, 1,   MDA↓, 1,   NRF2↑, 2,   ROS↓, 2,   mt-ROS?, 1,   SOD↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↓, 1,   ATP↑, 1,   Insulin↑, 1,   MMP↑, 1,   PGC-1α↝, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,   glucose↓, 1,  

Cell Death(tgid=5) ⓘ

Casp3↓, 2,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1↑, 1,   LC3II↑, 1,   p62↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

PARP1↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

PI3K↓, 1,  

Migration(tgid=13) ⓘ

VCAM-1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↑, 1,   IL10↑, 1,   IL18↓, 1,   IL1β↓, 2,   IL6↓, 1,   Inflam↓, 2,   pol-M2 MC↑, 1,   NF-kB↓, 1,   TNF-α↓, 2,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↑, 1,   AChE↓, 1,   BDNF↑, 1,   NGF↑, 1,   p‑tau↓, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   BioAv↑, 3,   Dose↝, 1,   eff↑, 2,   Half-Life↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   AST↓, 1,   GutMicro↑, 2,   IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiDiabetic↑, 1,   antiPs↑, 1,   cardioP↑, 1,   chemoP↑, 1,   cognitive↑, 1,   hepatoP↑, 1,   memory↑, 1,   neuroP↑, 3,   Obesity↓, 1,   radioP↑, 1,   toxicity↓, 2,  

Infection & Microbiome(tgid=24) ⓘ

AntiViral↑, 1,   Bacteria↓, 2,  
Total Targets: 66

Scientific Paper Hit Count for: PD-1, Programmed Death-1
2 Akkermansia
2 Formononetin
1 immunotherapy
1 Artemisinin
1 Boron
1 Capsaicin
1 Curcumin
1 Ellagic acid
1 Fucoidan
1 Luteolin
1 Niclosamide (Niclocide)
1 Resveratrol
1 Rosmarinic acid
1 Germacranolide sesquiterpene lactone
1 Urolithin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:709  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page